Have your say: We welcome your feedback to our current public consultations as we consider changes for pharmacy practice and how healthcare may be provided to the public in pharmacies.
Guidance for Pharmacists on the Safe Supply of Sumatriptan 50mg Tablets
Guidance for Pharmacists on the Safe Supply of Sumatriptan 50mg Tablets
In this guidance we highlight key points that should be considered by pharmacists in ensuring the safe supply of Sumatriptan 50mg Tablets. This product is licensed as a pharmacy only medicine for the treatment of adults aged 18 to 65 years, for the acute treatment of migraine attacks with or without aura, where a clear diagnosis of migraine has been previously made by a doctor.
Due to the need to confirm the patient’s diagnosis of migraine and the counselling requirements for the appropriate use of this product, Sumatriptan 50mg Tablets must only be supplied by the pharmacist.
The product’s Summary of Product Characteristics (SmPC) and Package Leaflet are available to view on the HPRA website.